9,375 Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) Acquired by AlphaMark Advisors LLC

AlphaMark Advisors LLC purchased a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 9,375 shares of the biotechnology company’s stock, valued at approximately $236,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Quantedge Capital Pte Ltd purchased a new stake in Corcept Therapeutics in the 4th quarter worth approximately $8,066,000. Norges Bank purchased a new stake in Corcept Therapeutics in the 4th quarter worth approximately $24,603,000. Linden Thomas Advisory Services LLC boosted its position in Corcept Therapeutics by 1.0% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 56,671 shares of the biotechnology company’s stock worth $1,841,000 after purchasing an additional 555 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Corcept Therapeutics by 4.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 900,444 shares of the biotechnology company’s stock worth $29,246,000 after purchasing an additional 39,111 shares in the last quarter. Finally, Jackson Creek Investment Advisors LLC purchased a new stake in Corcept Therapeutics in the 4th quarter worth approximately $1,110,000. Institutional investors and hedge funds own 93.61% of the company’s stock.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $30.21, for a total value of $66,462.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Corcept Therapeutics news, insider Joseph Douglas Lyon sold 10,830 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $26.00, for a total value of $281,580.00. Following the completion of the sale, the insider now directly owns 7,314 shares of the company’s stock, valued at approximately $190,164. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $30.21, for a total value of $66,462.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 91,700 shares of company stock worth $2,562,652. Corporate insiders own 20.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Corcept Therapeutics in a research report on Wednesday, May 29th. Piper Sandler restated an “overweight” rating and issued a $35.00 price objective on shares of Corcept Therapeutics in a research report on Monday. Truist Financial reiterated a “buy” rating and set a $65.00 target price on shares of Corcept Therapeutics in a research report on Monday, June 17th. Finally, StockNews.com lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 3rd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Corcept Therapeutics presently has a consensus rating of “Buy” and an average price target of $45.10.

Corcept Therapeutics Stock Performance

Shares of NASDAQ:CORT traded up $0.18 during midday trading on Monday, reaching $32.67. 1,177,522 shares of the company’s stock traded hands, compared to its average volume of 1,380,030. Corcept Therapeutics Incorporated has a 1 year low of $20.84 and a 1 year high of $35.22. The company has a market cap of $3.40 billion, a P/E ratio of 30.82 and a beta of 0.44. The company has a fifty day simple moving average of $28.58 and a two-hundred day simple moving average of $26.12.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.04. The firm had revenue of $146.80 million for the quarter, compared to analyst estimates of $141.19 million. Corcept Therapeutics had a return on equity of 24.19% and a net margin of 22.38%. The business’s revenue was up 38.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.14 EPS. As a group, research analysts forecast that Corcept Therapeutics Incorporated will post 0.95 EPS for the current fiscal year.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.